In the latest tranche of published warning letters, the US Food and Drug Administration (FDA) has continued to go after drugmakers for marketing glucagon-like peptide-1 (GLP-1) receptor agonists and similar medications without regulatory approval
"Novel therapeutic strategy to treat brain ischemia: overexpression of hepatocyte growth factor gene reduced ischemic injury without cerebral edema in rat model." Circulation
Key Takeaways Glutathione, a potent endogenous antioxidant, faces challenges in terms of bioavailability
Adverse Events and Treatment Discontinuation With GLP-1s, side effects are a common and expected consideration and can influence whether patients remain on treatment
Blood work before, during, and after treatment tracks IGF 1 levels, fasting glucose, and overall metabolic markers
Selecting I agree confirms the above and your acceptance of our Research Disclaimer and Terms of Sale